← Back to Search

Viscosupplementation

Euflexxa for Osteoarthritis

N/A
Waitlist Available
Led By Carlos A Higuera, MD
Research Sponsored by The Cleveland Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to 6 months
Awards & highlights
No Placebo-Only Group

Summary

This trial found that Euflexxa therapy can decrease levels of inflammatory and degenerative synovial fluid bio-markers in patients with knee osteoarthritis.

Eligible Conditions
  • Osteoarthritis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to 6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to 6 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in Hyaluronate Concentration
Secondary study objectives
Changes in Tumor Necrosis Factor-stimulated Gene 6 (TSG-6)
VAS Pain Score Improvement

Side effects data

From 2017 Phase 4 trial • 12 Patients • NCT01895959
8%
knee pain
100%
80%
60%
40%
20%
0%
Study treatment Arm
Treatment

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: EuflexxaExperimental Treatment1 Intervention
Two sets of Euflexxa injection at 0 and 6 months. Each set consists of 3 injections 1 week apart.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Euflexxa
2018
Completed Phase 4
~470

Find a Location

Who is running the clinical trial?

The Cleveland ClinicLead Sponsor
1,054 Previous Clinical Trials
1,371,417 Total Patients Enrolled
10 Trials studying Osteoarthritis
3,112 Patients Enrolled for Osteoarthritis
Carlos A Higuera, MDPrincipal InvestigatorThe Cleveland Clinic
2 Previous Clinical Trials
740 Total Patients Enrolled
~4 spots leftby Dec 2025